Evaluation of the Medicines Transparency Alliance Phase 1, 2008-2010

The Medicines Transparency Alliance (MeTA) was created in recognition of the key importance of access to medicines.

These documents report on:

  • Establishing a framework for MeTA in pilot countries; gaining government commitment and establishing sectoral and national committees.
  • Delivering against the MeTA objectives in countries; progress towards data identification, disclosure, changes in practice and logframe objectives.
  • The genesis of MeTA
  • International governance; the management board, advisory group, secretariat, private sector and civil society.
  • The MeTA hypotheses

The future of MeTA is examined including:

  • Funding mechanisms and identification of new funders
  • Governance arrangements
  • Identification of new countries
  • Whether to continue support to existing countries
  • The design and identification of the international secretariat function
  • What might be different?

Full Report: Evaluation of the Medicines Transparency Alliance Phase 1 2008-2010, Main Report [PDF- 940 KB]

Summary Report: Evaluation of the Medicines Transparency Alliance Phase 1 2008-2010, Summary Report [PDF- 240 KB]

Presentation: Evaluation of Medicines Transparency Alliance [PDF- 110 KB]

You may also be interested in

Comments

css.php